Clinical Trial Update: Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pemetrexed in combination with avelumab for MTAP-deficient metastatic urothelial carcinoma; currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Avelumab (Bavencio) (Avelumab)
• Pemetrexed (Alimta) (pemetrexed)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation | Phase 2 | Status: ACTIVE_NOT_RECRUITING